• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Atrial fibrillation predicts good functional outcome following intravenous tissue plasminogen activator in patients with severe stroke
Conclusion: Presence of AF was associated with favorable 90-day outcome following intravenous thrombolysis in patients with severe stroke at baseline, while the association did not exist in patients with mild stroke.
Source: Clinical Neurology and Neurosurgery - September 17, 2012 Category: Neurosurgery Authors: Sheng-Feng Sung, Yu-Wei Chen, Mei-Chiun Tseng, Cheung-Ter Ong, Huey-Juan Lin Tags: Original articles Source Type: research

The value of the use of plasma B-type natriuretic peptide among acute ischemic stroke patients in a Chinese emergency department
In this study, 142 of 238 acute ischemic stroke patients met the study criteria [mean age 70.84±11.48 years, 74 (52.11%) female]. Of the 142 patients, 35.92% were diagnosed with LAA at discharge, 25.35% with CE, 27.46% with SAO, 11.27% with SOE or SUE. Age, previous cardiac disease, atrial fibrillation, the length of hospital stays, SSS score on admission≤25 and mRS≥3 or death at discharge were all significantly higher in the CE patients compared to other subtypes (p
Source: Clinical Neurology and Neurosurgery - March 21, 2013 Category: Neurosurgery Authors: Wu Zhixin, Yang Lianhong, Huang Wei, Li Lianda, Jiang Longyuan, Zhang Yingjian, Wang Jinliang, He Mingfeng Tags: Original articles Source Type: research

Brain natriuretic peptide level on admission predicts recurrent stroke after discharge in stroke survivors with atrial fibrillation
Previous reports indicate that approximately 5–10% of patients with ischemic stroke in Japan experience a stroke recurrence within the first year [1,2]. Recurrent stroke results in further disabilities. Therefore, it is important to identify risk factors associated with recurrent stroke. Several factors have been shown to be associated with recurrent stroke including large artery atherosclerosis [3], diabetes mellitus [3], previous transient ischemic attack (TIA) [3], atrial fibrillation (AF) [3], hypertension [3], increasing age [3], fibrinogen levels [4,5], D-dimer levels [5], and C-reactive protein levels [6].
Source: Clinical Neurology and Neurosurgery - October 3, 2014 Category: Neurosurgery Authors: Kensaku Shibazaki, Kazumi Kimura, Junya Aoki, Kenichiro Sakai, Naoki Saji, Junichi Uemura Source Type: research

Rivaroxaban and intracranial haemorrhage after mild traumatic brain injury: A dangerous combination?
The novel direct anticoagulant rivaroxaban has been approved in 2011 for the prophylaxis of thromboembolic events in patients with atrial fibrillation. Its mechanisms of action involve direct inhibition of factor Xa and a large multicentre trial has demonstrated at least non-inferiority compared with warfarin regarding the prevention of ischemic stroke [1]. This trial has also demonstrated that the risk of major bleeding was not increased with rivaroxaban and indeed, intracranial and fatal bleeding occurred less frequently in rivaroxaban-treated patients.
Source: Clinical Neurology and Neurosurgery - May 30, 2015 Category: Neurosurgery Authors: Christopher Beynon, Anna Potzy, Oliver W. Sakowitz, Andreas W. Unterberg Source Type: research